++
Section 12: Rheumatologic Disorders
++
++
++
Risk factors for the development of osteoarthritis (OA) include:
++
++
++
++
++
B. Participation in running
++
++
++
++
++
++
+
+
++
++
++
Patient education for OA, such as programs in which volunteers regularly contact patients
++
++
++
A. Has not yet been demonstrated to provide benefit to OA patients
++
++
B. Is too expensive to recommend for general use by OA patients
++
++
C. Should emphasize the "wear and tear" nature of OA as part of the educational message
++
++
D. Has been shown to improve pain and functional status of OA patients
++
++
+
+
++
++
++
Matrix metalloproteinases (MMPs)
++
++
++
A. Are naturally occurring chemokines that work primarily by recruiting neutrophils and macrophages to the inflamed synovium
++
++
B. Help trigger degradation of articular cartilage by cleaving peptide bonds in proteoglycans
++
++
C. Are stimulated by tissue inhibitors of metalloproteinases (TIMPS)
++
++
D. Must be activated before they can ease the pain of OA
++
++
+
+
++
++
++
Which of the following are required for an accurate and appropriate diagnosis of OA?
++
++
++
A. Patient history and physical examination
++
++
B. Patient history, physical examination, and radiologic evaluation
++
++
C. Physical examination and magnetic resonance imaging
++
++
D. Patient history, physical examination, and positive response to pharmacologic treatment
++
++
E. Any of the above is accurate and appropriate
+
+
++
++
++
++
++
++
A. Is recommended as an appropriate initial treatment in OA
++
++
B. Should be given on a scheduled basis for optimal pain control
++
++
C. Can be associated with hepatotoxicity at doses below 4 g/day
++
++
D. Provides mild analgesia
++
++...